Johnson and Johnson report encouraging phase 1b trial data for their dual-targeting CAR-T therapy in relapsed/refractory large B-cell lymphoma. Among patients with one prior treatment, a 100% objective response rate was observed; the complete response rate reached 75% for those with multiple previous therapies. Safety profile showed no severe cytokine release syndrome, indicating potential for improved durable remission over single-antigen CAR-T therapies.